# Obstructive Sleep Apnea Diagnostic Testing

Select home sleep apnea testing only for medically uncomplicated adults with a high likelihood of moderate-to-severe obstructive sleep apnea; use attended polysomnography when comorbidity, alternate sleep pathology, hypoventilation risk, or a nondiagnostic home study could change management.

**Clinical question:** Which adults with suspected obstructive sleep apnea require polysomnography rather than home sleep apnea testing?

Updated: 2026-09-15T18:16:07.376303+00:00

## What matters in practice
- Do not diagnose adult OSA with questionnaires, clinical prediction tools, or consumer-device data alone; confirm with polysomnography (PSG) or technically adequate home sleep apnea testing (HSAT). [14][16]
- Use HSAT for medically uncomplicated adults whose history and examination indicate moderate-to-high pretest probability of OSA; a negative, inconclusive, or technically inadequate HSAT requires full-night PSG when suspicion persists. [14][18]
- Choose attended PSG initially when heart failure, prior stroke, significant cardiopulmonary disease, neuromuscular respiratory weakness, chronic opioid use, suspected hypoventilation, or another sleep disorder raises concern for nonobstructive sleep-disordered breathing or impaired HSAT accuracy. [15][18]
- Interpret HSAT respiratory event index cautiously: recording-time denominators and absent EEG-based sleep staging can underestimate event frequency and OSA severity compared with PSG-derived apnea-hypopnea index. [8][23][24]

## Choose PSG or HSAT after a comprehensive sleep evaluation

The test choice follows clinical phenotyping; it is not a screening-device decision.

Perform diagnostic testing only after a comprehensive sleep evaluation and arrange adequate follow-up to review study quality, phenotype, and management implications. PSG is the standard diagnostic test when OSA is suspected. Clinical tools, questionnaires, and prediction algorithms may support pretest assessment but must not establish the diagnosis without PSG or HSAT. [14][16]

Order HSAT when the adult is medically uncomplicated and clinical findings suggest at least moderate-to-high pretest probability of OSA. HSAT is not appropriate for population screening or asymptomatic persons because its intended use is diagnostic evaluation of selected symptomatic patients, not broad case finding. [18][19]

Order attended, in-laboratory PSG rather than HSAT when the result must distinguish obstructive from nonobstructive sleep-disordered breathing, quantify sleep-related hypoxemia, identify arousal-linked respiratory events, or assess a suspected comorbid sleep disorder. PSG includes EEG, electrooculography, and electromyography for sleep staging plus respiratory signals, oximetry, position, and leg-movement data; this broader signal set is the practical advantage over type III home testing. [24]
- Use PSG first for heart failure or prior stroke because these patients are at increased risk for central sleep apnea and sleep-related hypoxemia. [15]
- Use PSG first for significant cardiopulmonary disease, neuromuscular disease with respiratory muscle weakness, chronic opioid use, suspected hypoventilation, or suspected comorbid sleep disorders. [17][18]
- Consider PSG rather than HSAT in severe obesity, particularly BMI greater than 40 to 50, where HSAT may be less suitable. [18]
- Use PSG when an in-laboratory study is clinically necessary but also recognize that portable monitoring may be considered when laboratory PSG is not possible because of immobility, safety concerns, or critical illness. [17]

*Initial test selection for suspected adult OSA. [14][15][17][18][24]*

| Clinical scenario | Preferred diagnostic test | Reason the choice changes management |
| --- | --- | --- |
| Medically uncomplicated adult with moderate-to-high clinical likelihood of OSA | Technically adequate HSAT or PSG [14][18] | HSAT is an accepted diagnostic alternative in selected uncomplicated patients. [14][18] |
| Heart failure or prior stroke | Attended PSG [15] | Risk of central sleep apnea or sleep-related hypoxemia makes nonobstructive breathing assessment important. [15] |
| Significant cardiopulmonary disease, neuromuscular weakness, chronic opioid use, or suspected hypoventilation | Attended PSG [17][18] | These conditions can reduce HSAT accuracy or indicate nonobstructive sleep-disordered breathing. [17][18] |
| Insomnia, parasomnia, periodic limb movements, or another suspected sleep disorder | Attended PSG [17][24] | HSAT does not provide the sleep staging and auxiliary measurements needed to assess many comorbid sleep disorders. [17][24] |
| Negative, inconclusive, or technically inadequate HSAT with persistent clinical suspicion | Full-night PSG [18] | Proceed to PSG rather than treating the HSAT result as exclusionary. [18] |

## Interpret AHI and REI in the context of how the study measured sleep

A diagnostic index is only as reliable as its denominator, signals, and technical adequacy.

PSG reports the apnea-hypopnea index (AHI), the number of scored apneas and hypopneas per hour of sleep. OSA is commonly classified as mild at AHI at least 5 but less than 15 events/hour, moderate at least 15 but less than 30 events/hour, and severe at least 30 events/hour. An AHI of at least 5 events/hour establishes OSA in the cited diagnostic framework. [11]

HSAT commonly reports a respiratory event index (REI) based on recording or analyzed time rather than EEG-confirmed total sleep time. Because wake time may be included in the denominator and cortical-arousal–associated events are not captured, home respiratory polygraphy can underestimate obstructive event frequency and severity relative to PSG-based AHI. [8][23][24]

Review the raw study report for signal loss, body position, oxygenation data, and the relationship of symptoms to the measured event burden. Do not use oxygen desaturation index as an interchangeable substitute for AHI: ODI counts desaturations per hour, whereas AHI incorporates apnea and hypopnea scoring; hypopneas may be linked to desaturation or arousal on PSG. [22][24]
- A PSG apnea is airflow reduction of at least 90% from baseline lasting at least 10 seconds; a hypopnea is at least 30% airflow reduction for at least 10 seconds associated with at least 3% desaturation or an arousal in the cited scoring description. [22]
- A low or borderline REI does not reliably exclude OSA in a patient with high clinical suspicion, particularly when insomnia or prolonged wakefulness may enlarge recording time relative to actual sleep time. [18][23]
- A single-night study is the conventional diagnostic approach in uncomplicated suspected OSA, but night-to-night respiratory-event variability can misclassify some patients; reconsider PSG when the result conflicts materially with the clinical phenotype. [11]

*How study modality affects respiratory-event interpretation. [8][22][23][24]*

| Measure | What it counts | Key interpretation limitation |
| --- | --- | --- |
| PSG AHI | Apneas plus hypopneas per hour of EEG-defined sleep. [11][22][24] | Requires laboratory-grade physiologic recording and scoring but captures sleep time and arousal-linked events. [24] |
| HSAT REI | Respiratory events per recording or analyzed time rather than EEG-defined sleep time. [23][24] | Can underestimate event frequency and severity when wake time is included in the denominator. [23][24] |
| ODI | Oxygen desaturations per hour. [22] | Does not independently capture arousal-linked hypopneas and should not replace a diagnostic sleep study. [22][24] |
| Consumer wearable estimate | Device-derived estimates of sleep or respiratory parameters. [3][9] | Accuracy and validation vary; consumer devices should not replace clinical evaluation and diagnostic testing. [9] |

## Escalate after a negative or nondiagnostic HSAT

The highest-risk error is false reassurance from a home study that cannot answer the clinical question.

If HSAT is negative, inconclusive, or technically inadequate and the history still supports OSA, obtain a full-night PSG. This escalation is particularly important when the patient has sleep fragmentation, suspected insomnia, cardiopulmonary or neurologic disease, chronic opioid exposure, or findings suggesting central apnea or sleep-related hypoxemia. [15][18]

Do not repeat HSAT reflexively solely to obtain a more favorable number when the first study is discordant with the phenotype. PSG directly measures total sleep time and arousals and can identify respiratory, limb-movement, and sleep-architecture findings that a type III study cannot characterize. [18][24]

For patients with heart failure or prior stroke, avoid using an apparently reassuring HSAT result to rule out clinically important sleep-disordered breathing. In this group, AASM guidance favors attended PSG at initial diagnosis because central sleep apnea and sleep-related hypoxemia are clinically relevant alternatives. [15]
- Document the reason for PSG escalation: persistent high clinical suspicion, inadequate HSAT signals, concern for central events, unexplained nocturnal hypoxemia, or suspected comorbid sleep disorder. [15][17][18]
- Interpret a home study performed in a patient with insomnia cautiously because misestimation of total sleep time can distort event indices; a wrist-worn test in chronic insomnia overestimated total sleep time in a comparative PSG study. [22][23]
- If the clinical goal is evaluation of a non-CPAP OSA intervention, portable monitoring may be used to monitor response, but choose PSG when the follow-up question includes nonobstructive sleep-disordered breathing or another sleep disorder. [17][15]

*Actions after HSAT based on result and clinical concordance. [15][17][18][23][24]*

| HSAT result | Clinical context | Next action |
| --- | --- | --- |
| Positive and technically adequate | Uncomplicated adult with concordant moderate-to-high OSA probability | Use the confirmed diagnostic result for OSA management planning and ensure follow-up. [14][18] |
| Negative or low REI | Low pretest probability and no alternate sleep disorder suspected | Reassess the differential diagnosis and pursue further testing only if the clinical evaluation remains concerning. [14][18] |
| Negative or low REI | Persistent high suspicion, insomnia, or concern that recording time exceeded true sleep time | Obtain full-night PSG. [18][23][24] |
| Inconclusive or technically inadequate | Any patient in whom OSA remains a diagnostic concern | Obtain full-night PSG. [18] |
| Any HSAT result | Heart failure, prior stroke, chronic opioid use, neuromuscular weakness, significant cardiopulmonary disease, or suspected hypoventilation | Use attended PSG to characterize obstructive versus nonobstructive sleep-disordered breathing. [15][17][18] |

## Use wearable and oximetry data as adjuncts, not diagnostic replacements

Convenience does not substitute for validated diagnostic signals and clinical oversight.

Wearable, nearable, and software-based systems may improve access and raise clinical suspicion, but their accuracy and validation vary. Consumer devices should not replace clinical evaluation, PSG, or HSAT, and pulse-oximetry bias is a relevant limitation when interpreting oxygenation estimates. [9]

Peripheral arterial tonometry and wrist-based technologies can show useful diagnostic performance in selected populations, but device-specific performance does not eliminate the need to select testing according to comorbidity and the possibility of alternative sleep pathology. In a chronic-insomnia comparison study, a wrist-worn test using an AHI threshold of 15/hour had sensitivity 77.3% and specificity 100.0% for moderate-to-severe OSA, while the same device overestimated total sleep time and REM sleep relative to PSG. [22]

Do not use isolated overnight oximetry, ODI, or automated event counts to rule out OSA when the patient needs evaluation for arousal-associated respiratory events, central apnea, hypoventilation, or other sleep disorders. PSG is the modality that adds EEG-defined sleep, arousal scoring, respiratory effort, position, and limb-movement assessment. [22][24]
- Require physician or qualified sleep-medicine oversight of portable monitoring interpretation rather than relying on an automated report alone. [17]
- When pulse-oximetry findings are clinically discordant with symptoms or examination, prioritize a formal sleep study over consumer or single-channel measurements. [9][24]
- Use a validated HSAT pathway rather than a consumer wearable when an objective diagnosis is needed to direct treatment. [14][18]

*Practical roles for sleep-testing technologies. [9][14][17][18][24]*

| Technology | Appropriate role | Do not use as |
| --- | --- | --- |
| Attended PSG | Definitive initial testing when OSA is suspected and comorbidity or alternate sleep pathology may change interpretation. [14][15] | A test to reserve only for failed HSAT when PSG is indicated from the initial evaluation. [15][18] |
| Technically adequate HSAT | Diagnostic alternative for selected medically uncomplicated adults with moderate-to-high probability of OSA. [14][18] | A population screening test or a reliable exclusion test after a negative study in a high-suspicion patient. [18] |
| Portable respiratory monitoring | Alternative to PSG for high-probability moderate-to-severe OSA under qualified sleep-medicine oversight; may monitor non-CPAP treatment response. [17] | Testing for significant comorbidity or suspected comorbid sleep disorders. [17] |
| Consumer wearable or nearable device | Adjunct to awareness or longitudinal observation when clinically interpreted. [9] | A replacement for formal diagnostic evaluation. [9] |

## Match follow-up testing to the unanswered clinical question

Repeat testing is useful when it will clarify residual disease or a nonobstructive phenotype.

For longitudinal OSA care, use PSG or HSAT when follow-up testing will answer a management question rather than simply reproduce a prior diagnosis. Portable monitoring may be used to monitor response to non-CPAP OSA therapies. [17]

Prefer follow-up PSG in patients with cardiovascular disease when there is concern for central sleep apnea or sleep-related hypoxemia; AASM guidance specifically identifies heart failure and prior stroke as settings where PSG is favored over HSAT because of nonobstructive sleep-disordered breathing risk. [15]

When symptoms persist despite an apparently acceptable home-study result, reassess whether the unresolved problem is residual obstructive disease, central events, hypoxemia, insomnia, periodic limb movements, or another sleep disorder; PSG is the appropriate escalation test when that distinction is needed. [15][17][24]
- Use the same modality-selection logic at follow-up as at diagnosis: HSAT for selected uncomplicated obstructive-disease questions; PSG for central events, hypoxemia, sleep staging, or comorbid sleep-disorder assessment. [15][17][18]
- Document whether the follow-up objective is assessment of residual OSA, treatment response to a non-CPAP intervention, or evaluation of a new sleep-related symptom complex. [17][15]

*Follow-up testing choices in established OSA. [15][17][24]*

| Follow-up question | Testing approach | Reason |
| --- | --- | --- |
| Response to a non-CPAP OSA intervention | Portable monitoring may be used. [17] | Portable monitoring is identified as an option for monitoring response to non-CPAP treatment. [17] |
| Persistent symptoms with concern for insomnia, limb movements, central events, or hypoxemia | Attended PSG. [15][17][24] | PSG supplies sleep staging, arousal, respiratory, and auxiliary signals needed to separate these causes. [24] |
| Heart failure or prior stroke with a need to reassess sleep-disordered breathing | Attended PSG. [15] | These conditions increase concern for central sleep apnea and sleep-related hypoxemia. [15] |

## References
1. Diagnosis of Obstructive Sleep Apnea by Peripheral Arterial ... — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/1759186
2. A machine learning-based test for adult sleep apnoea ... — www.nature.com — https://www.nature.com/articles/s41598-020-62223-4
3. Wearable monitoring of sleep-disordered breathing: estimation of the apnea–hypopnea index using wrist-worn reflective photoplethysmography | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-020-69935-7
4. Nocturia and obstructive sleep apnoea | Nature Reviews Urology — www.nature.com — https://www.nature.com/articles/s41585-024-00887-7
5. Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome | Signal Transduction and Targeted Therapy — www.nature.com — https://www.nature.com/articles/s41392-023-01496-3
6. Endorsement of: “clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medicine clinical practice guideline” by the World Sleep Society - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1389945721000010
7. Comparison of home sleep apnea testing versus laboratory polysomnography for the diagnosis of obstructive sleep apnea in children - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165587617302616
8. Unattended home sleep studies for the diagnosis of obstructive sleep apnea in a population of French children - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1389945723000011
9. Sleep Diagnostics and Monitoring Technology in... : CONTINUUM: Lifelong Learning in Neurology — journals.lww.com — https://journals.lww.com/00132979-202608000-00004
10. Diagnosis of Obstructive Sleep Apnea Syndrome and Its Outcomes With Home Portable Monitoring - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0012369209601203
11. The effect of longitudinal sleep monitoring on... : Journal of Sleep Research — journals.lww.com — https://journals.lww.com/00061050-202405000-00038
12. Day-time split study for management of... : Lung India — journals.lww.com — https://journals.lww.com/01408641-202609000-00012
13. In-Home Testing for Obstructive Sleep Apnea | Continuum — journals.lww.com — https://journals.lww.com/continuum/fulltext/2013/02000/in_home_testing_for_obstructive_sleep_apnea.21.aspx
14. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28162150
15. Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults: an American Academy of Sleep Medicine clinical guidance statement - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314660
16. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline | Journal of Clinical Sleep Medicine | Springer Nature Link — www.ccjm.org — https://www.ccjm.org/lookup/external-ref?access_num=10.5664%2Fjcsm.6506&link_type=DOI
17. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/18198809
18. Home Sleep Apnea Testing for Obstructive Sleep Apnea - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10887466
19. The USPSTF and screening for obstructive sleep apnea: Dispelling misconceptions | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/index.php/content/84/6/429
20. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome | Pediatric Clinical Practice Guidelines & Policies | AAP Books | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/aapbooks/book/738/chapter/11733800/Diagnosis-and-Management-of-Childhood-Obstructive
21. Sleep Apnea Clinical Practice Guideline Quick Reference Tools | Pediatric Clinical Practice Guidelines & Policies | AAP Books | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/aapbooks/book/696/chapter/8471514/Sleep-Apnea-Clinical-Practice-Guideline-Quick
22. Performance of wrist-worn home sleep apnea testing (watch-PAT) among individuals with chronic insomnia: a comparative study with polysomnography - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13290634
23. Respiratory event index underestimates severity of sleep apnea compared to apnea-hypopnea index — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10805527
24. A comparison between auto-scored apnea-hypopnea index and oxygen desaturation index in the characterization of positional obstructive sleep apnea - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6634301

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.